![](https://nthumb.tpgimages.com/mid2_com_img/1339/29800/TOP27975037.jpg)
Osimertinib anti-cancer drug. A female patient taking an oral osimertinib tablet labelled AZ80, sold under the trade name Tagrisso. Osimertinib is used in the treatment of non-small cell lung carcinoma (NSCLC), and is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Patients taking this drug may develop resistance after approximately 10 months, and it can cause harm to the foetus so should be avoided by pregnant women. Osimertinib was approved for use by the EU in February 2016.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TOP27975037
Source:
達志影像
Authorization Type:
RM
Release Information:
須由TPG 完整授權
Model Release:
Yes
Property Release:
No
Right to Privacy:
No
Same folder images:
Restriction:
Editorial use only